157 results about "Psoriasis" patented technology

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The invention discloses application of pedunculoside in preparation of a medicine for treating psoriasis, and relates to the technical field of medicines. The invention provides a natural candidate drug which is clear in structure and has both effectiveness and safety for clinical treatment of psoriasis.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

The invention provides a preparation method of traditional Chinese medicine hydrogel for treating psoriasis, the hydrogel preparation is prepared from the following raw material medicines in parts by weight: 20-40 parts of PVA, 60-80 parts of borax, 20-40 parts of glycyrrhizic acid, 8-12 parts of paeoniflorin and 2-3 parts of glycerin, the hydrogel has the advantages of injectability, self-healing, stretchability and the like, can meet the requirements of skin dressing, can be tightly attached to the skin, and has a good application prospect. The separation is easy. Animal experiments prove that after being loaded with paeoniflorin, the gel has the curative effect of treating mild and moderate psoriasis, the treatment effect is remarkable, and the gel has a wide market application prospect.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

This invention discloses a class of PDE4 degrading agents or their pharmaceutical salts for treating psoriasis, with a general structural formula selected from one of the following structures: The PDE4 degrading agents for treating psoriasis provided by this invention offer a new strategy for in-depth research and development of novel structural types of anti-psoriasis drugs. The compounds of this invention exhibit excellent in vitro degradation activity against PDE4 protein.

The present invention relates to a flexible skin patch equipped with an ultra-thin LED assembly that emits light in a specific wavelength range and an invention for manufacturing the same, and is related to an invention capable of providing a flexible skin patch that has the excellent effect of promoting vitamin D production in a localized area of the skin, and has the effect of alleviating or treating local skin psoriasis, fungi, fungal tumors and eczema, and has excellent antiviral effect, and is easy to attach and detach.

Provided are a novel peptide inhibitor of the interleukin-23 receptor, a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Sesterterpenoid compounds and an extract L01 of Leucosceptrum canum, and use thereof in treatment of psoriasis are provided, belonging to the technical field of natural medicinal chemistry. The sesterterpenoid compound of the Leucosceptrum canum has a structure shown in any one of Formulas 9 to 12, which shows a highly rare backbone type, exhibits anti-inflammatory and immunosuppressive activities, and can be used in preparation of an anti-inflammatory drug and an immunosuppressive drug. A Leucosceptrum canum extract L01 having compounds 1 to 12 as characteristic ingredients, and use thereof in preparation of an anti-inflammatory drug and an immunosuppressive drug are further provided.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The invention relates to a preparation technology of composite pickles pickled in a soil jar. The composite pickles comprise the following raw materials: stems of psoriasis, a taste raw material, a flavor raw material and pre-prepared saline water. The process comprises the following steps: firstly, carrying out special treatment on the leaf beet stems: removing green leaves at the tail ends, repeatedly washing for three times to remove astringency, washing and cutting together with the taste raw materials, and airing until the surfaces do not have obvious moisture; the weight of the psoriasis is 10% of the weight of the psoriasis, the psoriasis is uniformly grabbed and kneaded, the materials are placed in a shade place for standing, then the psoriasis stems, the taste raw materials and the flavor raw materials are sequentially placed in an earth jar, the prefabricated saline water is added, the materials are sealed with water and naturally fermented, the storage temperature is controlled to be 16-20 DEG C, and the materials are stored for 24-24 hours. The overall fermentation time is greater than or equal to 180 days. According to the process, the psoriasis can keep crisp and tender mouth feel, the psoriasis and other raw materials form rich-level crisp feel, the composite flavor is coordinated, fermentation is stable, and finally the composite pickle which is high in mouth feel, full in flavor and stable in quality is obtained.

The invention discloses a targeting peptide for blocking combination of IL-17A and IL-17RA / RC and application thereof, the targeting peptide is selected from AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 or a combination of any one of AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 and IBP, the amino acid sequence of AZS-1 is as shown in SEQ ID NO: 1, the amino acid sequence of AZS-2 is as shown in SEQ ID NO: 2, the amino acid sequence of AZS-3 is as shown in SEQ ID NO: 3, the amino acid sequence of AZS-4 is as shown in SEQ ID NO: 4, and the amino acid sequence of AZS-5 is as shown in SEQ ID NO: 5. The amino acid sequence of the AZS-5 is as shown in SEQ ID NO: 5, and the amino acid sequence of the IBP is as shown in SEQ ID NO: 6. The targeting peptide provided by the invention has good tolerance, can generate effective interaction with the surface of a target protein, can realize specific binding with IL-17A, has relatively high blocking ability, can effectively improve symptoms of liver and kidney cell injury, cell edema and skin injury caused by psoriasis after being applied to a psoriasis mouse model, and has a good application prospect. The compound has a good application prospect in treatment and / or adjuvant therapy of IL-17A-mediated inflammatory diseases.

The present invention relates to methods of administering a cyclic peptide inhibitor of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding compositions, assays, methods, and / or uses for treatment of psoriasis.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating psoriasis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of 'CD177 + neutrophil-NETs' of psoriasis, the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the precise targeting function of CD177 peptide and the NETs inhibition function of a PADI4 inhibitor are creatively and organically integrated, and the constructed GNLC achieves the synergistic treatment effect of 'targeting enrichment-mechanism blocking-microenvironment remodeling'; meanwhile, excellent stability and safety are achieved, and a new precise treatment strategy far better than that in the prior art is provided for psoriasis.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention discloses a cream for treating erythroderma type psoriasis and a preparation method thereof, and belongs to the technical field of psoriasis drugs, the cream is prepared from the following raw materials by weight: 20-50 parts of cassia alata, 5-15 parts of prepared myrrh, 2-8 parts of raw rehmannia root, 40-160 parts of water, 40-50 parts of an emulsifier, and 0.05-0.1 part of a preservative. The preparation method comprises the following steps: decocting the cassia alata, the prepared myrrh and the radix rehmanniae recen in water, and then fishing out the medicinal materials to obtain medicine slurry; and mixing the medicine slurry, the emulsifier and the preservative, adding into an emulsifying machine, and emulsifying to obtain the product. The formula can be used for treating erythroderma type psoriasis, and the external emulsifiable paste for psoriasis has the effects of inhibiting various fungi and viruses, removing heat to cool blood, astringing and promoting tissue regeneration, inhibiting epidermal cell proliferation, slowing down epidermal metabolism cycle speed, promoting keratinogenesis, inhibiting sebum secretion and inhibiting the growth environment of bacteria and fungi. The inflammation cells are eliminated; the itching is relieved, and the like.

The invention provides a copolymer polypeptide as well as a pharmaceutical composition and application thereof. The copolymer polypeptide is formed by linear random copolymerization of a first monomer, a second monomer and a third monomer; the first monomer is selected from any one of alkaline amino acid and derivatives thereof; the second monomer is selected from any one of acidic amino acid and derivatives thereof; the third monomer is selected from any one of neutral amino acid and derivatives thereof. The copolymer polypeptide and the pharmaceutical composition thereof provided by the invention can effectively relieve hyperkeratosis caused by psoriasis, relieve inflammatory enteritis and effectively inhibit tumor growth.

This invention discloses a cream for treating psoriasis vulgaris and its preparation method: belonging to the technical field of psoriasis drug technology, this cream is made from the following raw materials in parts by weight: 1-5 parts Tripterygium wilfordii, 1-5 parts Euphorbia fischeriana, 10 parts Catechu, 8 parts Eucalyptus globulus, 10 parts Dictamnus dasycarpus, 10 parts Spatholobus suberectus, 10 parts Sophora flavescens, 10 parts Rehmannia glutinosa, 10 parts Angelica sinensis, 100-140 parts water, 40-50 parts emulsifier, and 0.05-0.1 parts preservative. The preparation method includes: decocting Tripterygium wilfordii, Euphorbia fischeriana, Catechu, Eucalyptus globulus, Dictamnus dasycarpus, Spatholobus suberectus, Sophora flavescens, Rehmannia glutinosa, and Angelica sinensis with water, then removing the herbs to obtain a medicinal paste; mixing the medicinal paste, emulsifier, and preservative and adding them to an emulsifier for emulsification to obtain the product. This formula can treat psoriasis vulgaris. As a topical cream for psoriasis, this invention has antifungal, antiviral, heat-clearing and blood-cooling, and antioxidant activities. It can inhibit epidermal cell proliferation, slow down the epidermal metabolic cycle, promote keratinization, inhibit sebum secretion, inhibit the growth environment of bacteria and fungi, and relieve itching caused by inflammation.

The invention belongs to the technical field of biological medicine, and discloses application of a small molecule compound Z57346765 and pharmaceutically acceptable salt thereof in preparation of a medicine for treating psoriasis. The Z57346765 and the pharmaceutically acceptable salt or the medicine thereof play a role in treating the psoriasis by inhibiting the expression or activity of the PGK1. The pharmaceutically acceptable carrier or excipient is selected from one or more of DMSO (Dimethylsulfoxide), PEG-300 (Polyethylene Glycol), Tween-80, normal saline, vegetable oil, mannitol, starch, lactose, magnesium stearate and hydroxypropyl methylcellulose.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation of one or more of the following proteins encoded by a corresponding gene transcript or portion thereof: S100A8; S100A9; and / or IL1RL2.

A sprayable polymeric scaffold composition for localized anti-inflammatory therapy is disclosed. The composition comprises lipid nanorods encapsulating inflammasome inhibitors, a thermogelling agent, and a thickening agent. The lipid nanorods, which can be formed using pyridoxine dipalmitate and DSPE-PEG (2000) carboxylic acid, inhibit NLRP3 and AIM2 inflammasomes, reducing inflammation. The thermogelling agent, such as poloxamer 407, enables the composition to transition from a fluid sol state at room temperature to a semi-solid gel state at body temperature, forming a localized gel film upon topical application. The thickening agent, such as mucin, enhances viscosity and provides additional anti-inflammatory effects. The composition delivers sustained release of encapsulated inhibitors, effectively reducing inflammatory markers and symptoms in conditions such as psoriasis. The sprayable scaffold offers a novel, localized treatment platform with improved skin penetration, ease of administration, and reduced systemic side effects.

A treatment for psoriasis is provided herein, wherein a human subject is administered a daily dose of 400 mg of compound 1 or a pharmaceutically acceptable salt thereof.

1. Name of the product subject to this design: Laser Therapy Device (EXC-5001). 2. Purpose of this design: For use by medical institutions as an adjunct treatment for psoriasis and vitiligo. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

To provide a compound in the manufacture of a medicament for treating diseases associated with overexpression or abnormal activation of JAK kinase and SYK kinase, including autoimmune diseases such as immune-mediated skin diseases (especially psoriasis, atopic dermatitis and SLE).SOLUTION: Provided is a compound of formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None